LENZ vs AEYE vs ALKT vs PRPH vs NVAX

For growth investors, Novavax, Inc.

(NVAX) is the stronger pick with 64. 7% revenue growth year-over-year, versus -84. 7% for ProPhase Labs, Inc. (PRPH). Novavax, Inc. (NVAX) offers the better valuation at 3. 6x trailing P/E, making it the more compelling value choice. Analysts rate LENZ Therapeutics, Inc. (LENZ) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Alkami Technology, Inc.

(ALKT) delivered a total return of -54. 9%, compared to -94. 8% for Novavax, Inc. (NVAX). Over 10 years, the gap is even starker: AEYE returned +96. 5% versus NVAX's -89. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alkami Technology, Inc.

(ALKT) is the lower-risk stock at 1. 23β versus ProPhase Labs, Inc. 's 2. 27β — meaning PRPH is approximately 85% more volatile than ALKT relative to the S&P 500. On balance sheet safety, LENZ Therapeutics, Inc. (LENZ) carries a lower debt/equity ratio of 0% versus 3% for ProPhase Labs, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Novavax, Inc.

(NVAX) is pulling ahead at 64. 7% versus -84. 7% for ProPhase Labs, Inc. (PRPH). On earnings-per-share growth, the picture is similar: Novavax, Inc. grew EPS 306. 5% year-over-year, compared to -166. 3% for ProPhase Labs, Inc.. Over a 3-year CAGR, ALKT leads at 29. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novavax, Inc.

(NVAX) is the more profitable company, earning 39. 2% net margin versus -788. 2% for ProPhase Labs, Inc. — meaning it keeps 39. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVAX leads at 50. 1% versus -570. 6% for PRPH. At the gross margin level — before operating expenses — LENZ leads at 97. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for LENZ: 431.

6% to $51. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Alkami Technology, Inc.

(ALKT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 23)). Novavax, Inc. (NVAX) carries a higher beta of 2. 22 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALKT: -58. 2%, NVAX: -89. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (LENZ (Healthcare) and AEYE (Technology) and ALKT (Technology) and PRPH (Healthcare) and NVAX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: LENZ is a small-cap quality compounder stock; AEYE is a small-cap quality compounder stock; ALKT is a small-cap high-growth stock; PRPH is a small-cap quality compounder stock; NVAX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.